<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171429</url>
  </required_header>
  <id_info>
    <org_study_id>GA28949</org_study_id>
    <secondary_id>2013-004277-27</secondary_id>
    <nct_id>NCT02171429</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2)</brief_title>
  <acronym>HIBISCUS II</acronym>
  <official_title>Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of Remission) and Safety of Etrolizumab Compared With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This Phase III, double-blind, placebo and active comparator controlled, multicenter study
      will investigate the efficacy and safety of etrolizumab in induction of remission in
      participants with moderately to severely active UC who are naIve to TNF inhibitors and
      refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2014</start_date>
  <completion_date type="Actual">May 25, 2020</completion_date>
  <primary_completion_date type="Actual">March 2, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Induction of Remission With Etrolizumab Compared With Placebo at Week 10, as Determined by the Mayo Clinic Score (MCS)</measure>
    <time_frame>Week 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Induction of Remission With Etrolizumab Compared With Adalimumab at Week 10, as Determined by the MCS</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Induction of Clinical Remission at Week 10, as Determined by the MCS</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response at Week 10, as Determined by the MCS</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement in Endoscopic Appearance of the Mucosa at Week 10, as Determined by the Mayo Endoscopic Subscore</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Endoscopic Remission at Week 10, as Determined by the Mayo Endoscopic Subscore</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Remission at Week 10 and who Maintained Remission to Week 14, as Determined by the MCS</measure>
    <time_frame>Week 10 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Histological Remission at Week 10, as Determined by the Nancy Histological Subscore</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MCS Rectal Bleeding Subscore at Week 6</measure>
    <time_frame>Baseline, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MCS Stool Frequency Subscore at Week 6</measure>
    <time_frame>Baseline, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ulcerative Colitis (UC) Bowel Movement Signs and Symptoms at Week 10, as Assessed by UC-Participant-Reported Outcome Signs and Symptoms (PRO/SS)</measure>
    <time_frame>Baseline, Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in UC Abdominal Symptoms at Week 10, as Assessed by UC-PRO/SS</measure>
    <time_frame>Baseline, Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health-Related Quality of Life (QOL) at Week 10, as Assessed by Overall Inflammatory Bowel Disease Questionnaire (IBDQ)</measure>
    <time_frame>Baseline, Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Etrolizumab: Serum Concentration</measure>
    <time_frame>Pre-dose (0 hour) on Day 1, Week 10, Week 14, early termination/end of safety follow-up (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One Adverse Event by Severity, According to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE v4.0)</measure>
    <time_frame>Baseline up to end of study (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One Serious Adverse Event</measure>
    <time_frame>Baseline up to end of study (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events Leading To Study Drug Discontinuation</measure>
    <time_frame>Baseline up to end of study (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Infection-Related Adverse Events by Severity, According to NCI CTCAE v4.0</measure>
    <time_frame>Baseline up to end of study (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serious Infection-Related Adverse Events</measure>
    <time_frame>Baseline up to end of study (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Injection-Site Reactions by Severity, According to NCI CTCAE v4.0</measure>
    <time_frame>Baseline up to end of study (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hypersensitivity Reaction Events by Severity, According to NCI CTCAE v4.0</measure>
    <time_frame>Baseline up to end of study (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to Etrolizumab</measure>
    <time_frame>Pre-dose (0 hour) on Day 1, Week 4, Week 10, Week 14, early termination/end of safety follow-up (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Laboratory Abnormalities</measure>
    <time_frame>Baseline (Day 1), Week 10, and any unscheduled visits or early withdrawal from treatment, up to end of study (up to Week 26)</time_frame>
    <description>Laboratory parameters for hematology, blood chemistry, and urinalysis will be measured compared with a standard reference range. Values outside the standard reference range are considered abnormalities. Not every laboratory abnormality qualifies as an adverse event. A laboratory test result must be reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment or a medical intervention; or is clinically significant in the investigator's judgment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">358</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Adalimumab + Etrolizumab Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etrolizumab + Adalimumab Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etrolizumab Placebo + Adalimumab Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.</description>
    <arm_group_label>Adalimumab + Etrolizumab Placebo</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adalimumab Placebo</intervention_name>
    <description>Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6 and 8.</description>
    <arm_group_label>Etrolizumab + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Etrolizumab Placebo + Adalimumab Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etrolizumab</intervention_name>
    <description>Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W).</description>
    <arm_group_label>Etrolizumab + Adalimumab Placebo</arm_group_label>
    <other_name>PRO145223</other_name>
    <other_name>RO5490261</other_name>
    <other_name>RG7413</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Etrolizumab Placebo</intervention_name>
    <description>Placebo matching to etrolizumab will be administered SC Q4W.</description>
    <arm_group_label>Adalimumab + Etrolizumab Placebo</arm_group_label>
    <arm_group_label>Etrolizumab Placebo + Adalimumab Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of UC established at least 3 months prior to randomization (Day 1)

          -  Moderately to severely active UC as determined by the MCS

          -  Naive to treatment with TNF inhibitor therapy

          -  An inadequate response, loss of response, or intolerance to prior corticosteroid
             and/or immunosuppressant treatment

          -  Background UC therapy may include oral 5-aminosalisylate (5-ASA), budesonide, oral
             corticosteroids, probiotics, azathioprine (AZA), 6-mercaptopurine (6MP), or
             methotrexate (MTX) if doses have been stable for:

          -  AZA, 6-MP, MTX: 8 weeks immediately prior to randomization

          -  5-ASA: 4 weeks immediately prior to randomization

          -  Corticosteroids: 4 weeks immediately prior to randomization; if corticosteroids are
             being tapered, dose has to be stable for at least 2 weeks prior to randomization

          -  Use of highly effective contraception method as defined by the protocol

          -  Have received a colonoscopy within the past year or be willing to undergo a
             colonoscopy in lieu of a flexible sigmoidoscopy at screening

        Exclusion Criteria:

        Exclusion Criteria Related to Inflammatory Bowel Disease:

          -  Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for
             UC

          -  Past or present ileostomy or colostomy

          -  Diagnosis of indeterminate colitis

          -  Suspicion of ischemic colitis, radiation colitis, or microscopic colitis

          -  Diagnosis of toxic megacolon within 12 months of initial screening visit

          -  Any diagnosis of Crohn's disease

          -  Past or present fistula or abdominal abscess

          -  A history or current evidence of colonic mucosal dysplasia

          -  Patients with any stricture (stenosis) of the colon

          -  Patients with history or evidence of adenomatous colonic polyps that have not been
             removed

        Exclusion Criteria Related to Prior or Concomitant Therapy:

          -  Prior treatment with TNF-alpha antagonists

          -  Any prior treatment with etrolizumab or other anti integrin agents

          -  Any prior treatment with rituximab

          -  Any treatment with tofacitinib during screening

          -  Any prior treatment with anti-adhesion molecules

          -  Use of IV steroids within 30 days prior to screening with the exception of a single
             administration of IV steroid

          -  Use of agents that deplete B or T cells

          -  Use of anakinra, abatacept, cyclosporine, sirolimus, or mycophenolate mofetil (MMF)
             within 4 weeks prior to randomization

          -  Chronic nonsteroidal anti inflammatory drug (NSAID) use

          -  Patients who are currently using anticoagulants including, but not limited to,
             warfarin, heparin, enoxaparin, dabigatran, apixaban, rivaroxaban

          -  Patients who have received treatment with corticosteroid enemas/suppositories and/or
             topical (rectal) 5 ASA preparations within 2 weeks prior to randomization

          -  Apheresis (i.e., Adacolumn apheresis) within 2 weeks prior to randomization

          -  Received any investigational treatment including investigational vaccines within 5
             half lives of the investigational product or 28 days after the last dose, whichever is
             greater, prior to randomization

          -  History of moderate or severe allergic or anaphylactic/anaphylactoid reactions to
             chimeric, human, or humanized antibodies, fusion proteins, or murine proteins or
             hypersensitivity to etrolizumab (active drug substance) or any of the excipients (L
             histidine, L-arginine, succinic acid, polysorbate 20)

          -  Patients administered tube feeding, defined formula diets, or parenteral
             alimentation/nutrition who have not discontinued these treatments within 3 weeks prior
             to randomization

        Exclusion Criteria Related to General Safety:

          -  Pregnant or lactating

          -  Lack of peripheral venous access

          -  Hospitalization (other than for elective reasons) during the screening period

          -  Significant uncontrolled comorbidity, such as cardiac (e.g., moderate to severe heart
             failure New York Heart Association Class III/IV), pulmonary, renal, hepatic,
             endocrine, or gastrointestinal disorders

          -  Neurological conditions or diseases that may interfere with monitoring for PML

          -  History of demyelinating disease

          -  Clinically significant abnormalities on screening neurologic examination (PML
             Objective Checklist)

          -  Clinically significant abnormalities on the screening PML Subjective Checklist

          -  History of alcohol, drug, or chemical abuse less than 6 months prior to screening

          -  Conditions other than UC that could require treatment with &gt; 10 mg/day of prednisone
             (or equivalent) during the course of the study

          -  History of cancer, including hematologic malignancy, solid tumors, and carcinoma in
             situ, within 5 years before screening

        Exclusion Criteria Related to Infection Risk

          -  Congenital or acquired immune deficiency

          -  Patients must undergo screening for HIV and test positive for preliminary and
             confirmatory tests

          -  Positive hepatitis C virus (HCV) antibody test result

          -  Positive hepatitis B virus (HBV) antibody test result

          -  Evidence of or treatment for Clostridium difficile (as assessed by C. difficile toxin
             testing) within 60 days prior to randomization or other intestinal pathogens (as
             assessed by stool culture and ova and parasite evaluation) within 30 days prior to
             randomization

          -  Evidence of or treatment for clinically significant cytomegalovirus (CMV) colitis
             (based on the investigator's judgment) within 60 days prior to randomization

          -  History of active or latent TB

          -  History of recurrent opportunistic infections and/or history of severe disseminated
             viral infections

          -  Any serious opportunistic infection within the last 6 months prior to screening

          -  Any current or recent signs or symptoms (within 4 weeks before screening and during
             screening) of infection

          -  Any major episode of infection requiring treatment with IV antibiotics within 8 weeks
             prior to screening or oral antibiotics within 4 weeks prior to screening

          -  Received a live attenuated vaccine within 4 weeks prior to randomization

          -  History of organ transplant

        Exclusion Criteria Related to Laboratory Abnormalities (at Screening)

          -  Serum creatinine &gt;2 x upper limit of normal (ULN)

          -  ALT or AST &gt; 3 x ULN or alkaline phosphatase &gt; 3 x ULN or total bilirubin &gt; 2.5 x ULN

          -  Platelet count &lt; 100,000/uL

          -  Hemoglobin &lt; 8 g/dL

          -  Absolute neutrophil count &lt; 1500/uL

          -  Absolute lymphocyte count &lt; 500/uL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valley Gastroenterology Consultants</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Doctors</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Digestive Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Specialists</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Clinical Research Center, Digestive Health</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regents of the University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute, LLC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center IRB</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Gastroenterology Research, LLC</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah HSC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Medicas Mar Del Plata</name>
      <address>
        <city>Mar del Plata</city>
        <zip>B7600DHK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico CER</name>
      <address>
        <city>Quilmes</city>
        <zip>B1878DVB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Footscray Hospital; Gastroenterology</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Prof Edgar Santos-Ufba; Ambulatorio Magalhaes Neto 3Andar- Dermatologia</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>41110-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará X</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <zip>60430-370</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Digestivo de Curitiba</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80430-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ernesto Dornelles</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90160-092</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pesquisare Saúde Sociedade Simples</name>
      <address>
        <city>Santo Andre</city>
        <state>SP</state>
        <zip>09080-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre &quot;Asklepii&quot;, OOD</name>
      <address>
        <city>Dupnitsa</city>
        <zip>2600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCC Sv. Pantaleymon OOD</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical center Medconsult Pleven OOD</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT - Ruse, AD</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Hadzhi Dimitar&quot;, OOD</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;City Clinic UMHAC&quot; EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical center CONVEX EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1680</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Nov Rehabilitatsionen Tsentar&quot;, EOOD</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT 'Sv. Marina', EAD</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTS - Fundación Valle de Lili</name>
      <address>
        <city>Cali</city>
        <zip>0</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Coloproctologia ICO S.A.S.</name>
      <address>
        <city>Medellin</city>
        <zip>050025</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Pula</name>
      <address>
        <city>Pula</city>
        <zip>52100</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Dubrava</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Sveti Duh</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepato-Gastroenterologie HK, s.r.o.</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 12</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PreventaMed, s.r.o.</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mestska nemocnice Ostrava p.o.</name>
      <address>
        <city>Ostrava</city>
        <zip>702000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pardubicka krajska nemocnice, a.s.</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISCARE a.s.</name>
      <address>
        <city>Praha 7</city>
        <zip>170 04</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion</name>
      <address>
        <city>Herakleion</city>
        <zip>711 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Outpatient Clinic</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Diseases Center &quot;Gastro&quot;</name>
      <address>
        <city>Riga</city>
        <zip>LV-1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Rīga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health. Sciences Kaunas Clinics</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipeda Seamen's Hospital, Public Institution</name>
      <address>
        <city>Klaipeda</city>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu Clinic, Public Institution; Cardiology</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Raja Perempuan Zainab II; Department of Medicine</name>
      <address>
        <city>Kota Bahru</city>
        <zip>15586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusat Perubatan Universiti Kebangsaan Malaysia</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Tengku Ampuan Afzan</name>
      <address>
        <city>Pahang</city>
        <zip>25100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>0620</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3248</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shakespeare Specialist Group</name>
      <address>
        <city>Takapuna</city>
        <zip>0620</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tauranga Hospital</name>
      <address>
        <city>Tauranga</city>
        <zip>3143</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne LUKA MED.Joanna Łuka</name>
      <address>
        <city>Chojnice</city>
        <zip>89-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pro Familia Altera Sp z o.o.</name>
      <address>
        <city>Katowice</city>
        <zip>40-645</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz All-Medicus</name>
      <address>
        <city>Katowice</city>
        <zip>40-660</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne im. prof. K. Gibinskiego SUM</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Opieki Zdrowotnej Orkan-Med</name>
      <address>
        <city>Ksawerow</city>
        <zip>95-054</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allmedica Badania Kliniczne Sp z o.o. Sp K.</name>
      <address>
        <city>Nowy Targ</city>
        <zip>34-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Medyk</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski, Bartosz Korczowski</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej SONOMED</name>
      <address>
        <city>Szczecin</city>
        <zip>70-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoterapia PFG Sp. z o.o.</name>
      <address>
        <city>Warszawa</city>
        <zip>02-653</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioVirtus Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-797</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LexMedica Osrodek Badan Klinicznych</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-114</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AppleTreeClinics Sp. z o.o.</name>
      <address>
        <city>Łódź</city>
        <zip>90-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Clinic</name>
      <address>
        <city>Sankt-peterburg</city>
        <state>Sankt Petersburg</state>
        <zip>191119</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBIH City Clinical Hospital #31</name>
      <address>
        <city>Sankt-peterburg</city>
        <state>Sankt Petersburg</state>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI HPE Altai State Medical University of MoH and SD; Out-patient Department</name>
      <address>
        <city>Barnaul</city>
        <zip>656038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irkutsk State Medical Academy of Continuing Education</name>
      <address>
        <city>Irkutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Scientific Research Institute of Physyology and Basic Medicine&quot; under the SB of RAMS</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630117</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BHI of Omsk region Clinical Oncology Dispensary</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Emergency and Radiation Medicine; Pulmonology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pavlov First Saint Petersburg State Medical University</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb SHI &quot;City Hospital #9&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBEI HE &quot;Stavropol State Medical University&quot; of Ministry of Healthcare of Russian Federation</name>
      <address>
        <city>Stavropol</city>
        <zip>355018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Voronezh Regional Clinical Hospital #1</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Diskapi Yildirim Beyazit Training and Research Hospital; Gastroenterology</name>
      <address>
        <city>Ankara</city>
        <zip>06110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gaziantep University Medical Faculty Sahinbey Educational Research Hospital; Medical Oncology</name>
      <address>
        <city>Gaziantep</city>
        <zip>27310</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa Medical Faculty; Obstetrics and Gynecology</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haydarpasa Numune Training and Research Hospital; Gastroenterology</name>
      <address>
        <city>Istanbul</city>
        <zip>34668</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara University Pendik Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kocaeli Universitesi Tip Fakultesi</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI of SRC Sumy RCH Dept of Gasroenterology Sumy SU MI</name>
      <address>
        <city>Sumy</city>
        <state>Kharkiv Governorate</state>
        <zip>40022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ternopil University Hospital</name>
      <address>
        <city>Ternopil</city>
        <state>Kherson Governorate</state>
        <zip>46002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI of Kyiv RC Kyiv Regional Clinical Hospital</name>
      <address>
        <city>Kyiv</city>
        <state>KIEV Governorate</state>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Center of International Institute of Clinical Trials LLC; Medical Center &quot;OK!Clinic+&quot;</name>
      <address>
        <city>Kyiv</city>
        <state>KIEV Governorate</state>
        <zip>2091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.Novak Transcarpathian Regional Clinical Hospital</name>
      <address>
        <city>Uzhgorod</city>
        <state>KIEV Governorate</state>
        <zip>88018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCNECRCH Dept of Surgery, SHEI Ukr BSMU</name>
      <address>
        <city>Chernivtsi</city>
        <state>Podolia Governorate</state>
        <zip>58002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI City Hospital #1</name>
      <address>
        <city>Zaporizhzhia</city>
        <state>Tavria Okruha</state>
        <zip>69104</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI inst. of Gastroenterology of NAMSU Dept of Stomach &amp; Duodenum Diseases, D&amp;ThN SI DMA of MoHU</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49074</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI Kherson Afanasii and Olha Tropiny City Clinical Hospital</name>
      <address>
        <city>Kherson</city>
        <zip>73000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv CCH #18 Dept of Proctology O. O. Bogomolets NMU</name>
      <address>
        <city>Kyiv</city>
        <zip>01030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.V. Sklifosovskyi Poltava RCH Dept of Gastroenterology HSEIU UMSA</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Small Enterprise Medical Center Pulse</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.I. Pyrogov VRCH Dept of Gastroenterology M.I. Pyrogov VNMU</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCIC MC LLC Health Clinic</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaporizhzhia SMU</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69104</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Diaservis</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69106</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>rhuMAb Beta7</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

